Tolerogenic vaccines for Multiple Sclerosis

ECU Author/Contributor (non-ECU co-authors, if there are any, appear on document)

II,Alan D. Curtis (Creator)

Mark D. Mannie (Creator)

Institution

East Carolina University (ECU )

Web Site: http://www.ecu.edu/lib/

Abstract: Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized in the generation of tolerogenic vaccines that inhibit experimental autoimmune encephalomyelitis in a preclinical setting, and these vaccines may be a prequel of the tolerogenic vaccines that may have therapeutic benefit in Multiple Sclerosis. The purpose here is to provide a snapshot of the current concepts and future prospects of tolerogenic vaccination for Multiple Sclerosis, along with the central challenges to clinical application.

Additional Information

Publication

Other

Human Vaccines & Immunotherapeutics; 9:5 p. 1032-1038

Language: English

Date: 2013

Keywords

autoimmune disease, vaccine, experimental autoimmune encephalomyelitis, T lymphocytes, tolerance, myelin, multiple sclerosis, immune, neuroantigen, therapy

Email this document to